WHO ICTRP trial
A prospective multicentre phase II trial of zoledronic acid in patients with…
EUCTR2005-003985-40-BE · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2005-003985-40-BE |
|---|---|
| Public title | A prospective multicentre phase II trial of zoledronic acid in patients with myelofibrosis with myeloid metaplasia (MMM) - zoledronic acid in myelofibrosis |
| Scientific title | A prospective multicentre phase II trial of zoledronic acid in patients with myelofibrosis with myeloid metaplasia (MMM) - zoledronic acid in myelofibrosis |
| Primary sponsor | Department of Internal Medicine, University Hospital Gasthuisberg |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | France;Spain;Belgium;Germany |
| Conditions | myelofibrosis with myeloid metaplasia |
| Interventions | Trade Name: Zometa Product Name: Zometa Product Code: EU/1/01/176/001-003 Pharmaceutical Form: Intravenous infusion |
| Registration date | Dec 16, 2005 |
| Target size | 30 |
| Secondary IDs | CZOL446G2422 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- Yes Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: